HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that management will be
providing an overview of the business and company updates at the
H.C. Wainwright & Co. 23rd Annual Global Investment Conference
taking place September 13-15, 2021,
and at the Cantor Fitzgerald Virtual Global Healthcare Conference
taking place September 27-30,
2021.
The presentation dates and times for the September investor
conferences are:
H.C. Wainwright & Co. 23rd Annual Global
Investment Conference on Monday,
September 13, 2021, at 9:00 AM
ET in a virtual presentation available for on-demand
viewing.
Cantor Fitzgerald Virtual Global Healthcare Conference
on Wednesday, September 22, 2021, at 2:00 PM ET in a virtual presentation.
Interested parties may access the on-demand and live webcast
links of both events by visiting the Company's website at
http://ir.acelrx.com/upcoming-events. Management will
also be hosting one-on-one virtual investor meetings throughout the
days of each conference.
For those not available to listen to the live webcast, a replay
will be archived for 90 days and available through the Investors
page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. AcelRx has one approved
product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30
mcg), known as DZUVEO® in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and one product candidate, Zalviso®
(sufentanil sublingual tablet system, SST system, 15 mcg), an
investigational product in the U.S., is being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. AcelRx has obtained the rights to file New Drug
Applications (NDAs) and, subject to U.S. Food and Drug
Administration (FDA) approval, commercialize in the U.S. two of
Laboratoire Aguettant's innovative, EU-approved, pre-filled syringe
products – ready-to-use ephedrine and phenylephrine. DZUVEO and
Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-in-two-september-investor-conferences-301373584.html
SOURCE AcelRx Pharmaceuticals, Inc.